Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

BACKGROUND: Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over. METHODS: We bring pioneering con...

Descripción completa

Detalles Bibliográficos
Autores principales: Grenfell, Rafaella F. Q., Almeida, Nathalie B. F., Filgueiras, Priscilla S., Corsini, Camila A., Gomes, Sarah V. C., de Miranda, Daniel A. P., Lourenço, Adelina J., Martins-Filho, Olindo A., de Oliveira, Jaquelline G., Teixeira-Carvalho, Andrea, Campos, Guilherme R. F., Nogueira, Mauricio L., Alves, Pedro Augusto, Fernandes, Gabriel R., Castilho, Leda R., Lima, Tulio M., de Abreu, Daniel P. B., Alvim, Renata G. F., Silva, Thaís Bárbara de S., Jeremias, Wander de J., Otta, Dayane A., Campi-Azevedo, Ana Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218743/
https://www.ncbi.nlm.nih.gov/pubmed/35757764
http://dx.doi.org/10.3389/fimmu.2022.918896

Ejemplares similares

Ejemplares similares